Manufacturer of Controlled Substances; Notice of Application, 40331 [E7-14267]

Download as PDF Federal Register / Vol. 72, No. 141 / Tuesday, July 24, 2007 / Notices 40331 activity of the group research project. Membership in this group research project remains open, and IMS Global Learning Consortium, Inc. intends to file additional written notifications disclosing all changes in membership. On April 7, 2000, IMS Global Learning Consortium, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on September 13, 2000 (65 FR 55283). The last notification was filed with the Department on March 16, 2007. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on May 7, 2007 (72 FR 25781). Schedule and Explosives Programs Division (AEPD) of the Bureau of Alcohol, Tobacco, Firearms and Explosives distributes program-specific customer satisfaction surveys to more effectively capture customer perception/ satisfaction of services. AEPD’s strategy is based on a commitment to provide the kind of customer service that will better accomplish ATF’s mission. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 500 respondents will complete a 15 minute survey. (6) An estimate of the total public burden (in hours) associated with the collection: There are an estimated 125 annual total burden hours associated with this collection. If additional information is required contact Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: July 18, 2007. Lynn Bryant, Department Clearance Officer, PRA, Department of Justice. [FR Doc. E7–14244 Filed 7–23–07; 8:45 am] BILLING CODE 4410–FY–P DEPARTMENT OF JUSTICE Antitrust Division mstockstill on PROD1PC66 with NOTICES Notice Pursuant to the National Cooperative Research and Production Act of 1993—IMS Global Learning Consortium, Inc. Notice is hereby given that, on June 15, 2007, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), IMS Global Learning Consortium, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Agilix, Orem, UT; Florida Virtual Schools, Orlando, FL; Houghton Mifflin Company, Boston, MA; Sungard Higher Education, Malvern, PA; and Sun Microsystems, Inc., Broomfield, CO have been added as parties to this venture. No other changes have been made in either the membership or planned VerDate Aug<31>2005 17:50 Jul 23, 2007 Jkt 211001 Patricia A. Brink, Deputy Director of Operations, Antitrust Division. [FR Doc. 07–3592 Filed 7–23–07; 8:45 am] BILLING CODE 4410–11–M DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 23, 2007, American Radiolabeled Chemical, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Dextropropoxyphene, bulk (nondosage forms)(9273). Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Phenazocine (9715) ..................... Fentanyl (9801) ............................ II II II II II II The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 24, 2007. Dated: July 10, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–14267 Filed 7–23–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Schedule Gamma hydroxybutyric acid (2010). Ibogaine (7260) ............................ Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... Dimethyltryptamine (7435) ........... 1-[1-(2-Thienyl) ............................. cyclohexyl]piperidine(7470) .......... Dihydromorphine (9145) ............... Normorphine (9313) ..................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Phencyclidine (7471) .................... Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Meperidine (9230) ........................ Metazocine (9240) ........................ PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 I I I I I I I I II II II II II II II II II II II II II II Manufacturer of Controlled Substances; Notice of Application Pursuant to 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 24, 2007, Applied Science Labs, Division of Alltech Associates Inc., 2701 Carolean Industrial Drive, State College, Pennsylvania 16801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ N,N-Dimethylamphetamine (1480) 4-Methylaminorex (cis isomer) (1590). Alpha-ethyltryptamine (7249) ....... E:\FR\FM\24JYN1.SGM 24JYN1 Schedule I I I I I

Agencies

[Federal Register Volume 72, Number 141 (Tuesday, July 24, 2007)]
[Notices]
[Page 40331]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-14267]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 23, 2007, American 
Radiolabeled Chemical, Inc., 101 Arc Drive, St. Louis, Missouri 63146, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma hydroxybutyric acid (2010)...........  I
Ibogaine (7260)............................  I
Lysergic acid diethylamide (7315)..........  I
Tetrahydrocannabinols (7370)...............  I
Dimethyltryptamine (7435)..................  I
1-[1-(2-Thienyl)...........................  I
cyclohexyl]piperidine(7470)................
Dihydromorphine (9145).....................  I
Normorphine (9313).........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Phencyclidine (7471).......................  II
Phenylacetone (8501).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Meperidine (9230)..........................  II
Metazocine (9240)..........................  II
Dextropropoxyphene, bulk (non-dosage         II
 forms)(9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Phenazocine (9715).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances as radiolabeled compounds for biochemical 
research.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 2401 
Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed 
no later than September 24, 2007.

    Dated: July 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-14267 Filed 7-23-07; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.